



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Eohilia (budesonide suspension) Page: 1 of 2

Effective Date: 7/1/2024 Last Review Date: 5/15/2024

Applies to:  Illinois  New Jersey  Pennsylvania Kids  
 Maryland  Florida Kids  Virginia

### Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Eohilia (budesonide suspension) under the patient's prescription drug benefit.

### Description:

#### FDA-Approved Indication

Eohilia is indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE).

#### Limitations of Use

Eohilia has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks.

### Applicable Drug List:

Eohilia

### Policy/Guideline:

#### Criteria for Approval:

**The requested drug will be covered with prior authorization when the following criteria are met:**

- The patient has the diagnosis of eosinophilic esophagitis (EoE). Documentation is required for approval.

**AND**

- The patient is 11 years of age or older

**AND**

- The request is NOT for continuation of therapy

**AND**

- The patient has a history of clinical symptoms of esophageal dysfunction (e.g., eating problems, abdominal pain, heartburn, dysphagia, vomiting, food impaction, weight loss) at baseline

**OR**

- The request is for continuation of therapy

**AND**

- The patient has achieved or maintained a positive clinical response (e.g., improvement in symptoms of esophageal dysfunction, histologic remission on biopsy). [Documentation is required for approval.]



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Eohilia (budesonide suspension) Page: 2 of 2

Effective Date: 7/1/2024 Last Review Date: 5/15/2024

Applies to:  Illinois  New Jersey  Pennsylvania Kids  
 Maryland  Florida Kids  Virginia

### Approval Duration and Quantity Restrictions:

**Initial Approval:** 6 months

**Renewal Approval:** 12 months

**Quantity Level Limit:** 60 single-dose stick packs per 30 days

### References:

1. Eohilia [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; February 2024.
2. Lexicomp Online, Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed February 29, 2024.
3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 02/29/2024).
4. Dellon E, Gonsalves N, Hirano I, et al. ACG Clinical Guideline: Evidenced Based Approach to the Diagnosis and Management of Esophageal Eosinophilia and Eosinophilic Esophagitis (EoE). Am J Gastroenterol. 2013;108:679–692.
5. Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology. 2020;158(6):1776-1786.